'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective

Clark, A.D., Gordon, W.C., Walker, I.D. and Tait, R.C. (2004) 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sanguinis, 86(2), pp. 120-124. (doi: 10.1111/j.0042-9007.2004.00393.x) (PMID:15023181)

Full text not currently available from Enlighten.

Abstract

Background and Objectives: The aim of this retrospective study was to assess the effect of activated recombinant factor VII (rFVIIa) on the natural history of massive transfusion episodes. Materials and Methods: During 2002, outcome parameters were assessed in 50 patients transfused with more than 10 units of packed red cells. The effect of the addition of rFVIIa in 10 patients, with intractable bleeding, was then observed. Results: Overall mortality was 20% at 24 h and 34% at 7 days. Severe coagulopathy was confirmed as a serious negative prognostic factor and occurred in 42% of patients overall, but in 70% of rFVIIa‐treated patients. Transient cessation or reduction of bleeding was noted in 60% of patients following rFVIIa infusion. However, 24‐h and 7‐day mortality rates were 40% and 70%, respectively, in this group. Conclusions: Last‐ditch rFVIIa therapy in patients resistant to conventional treatment did not rescue these patients or significantly alter outcomes.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Clark, Dr Andrew and Walker, Prof Isobel and Tait, Dr Robert
Authors: Clark, A.D., Gordon, W.C., Walker, I.D., and Tait, R.C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Vox Sanguinis
Publisher:Blackwell Publishing
ISSN:0042-9007
ISSN (Online):1423-0410
Published Online:15 March 2004

University Staff: Request a correction | Enlighten Editors: Update this record